Apr 10 |
Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
|
Mar 18 |
Cyclo Therapeutics reports FY results
|
Mar 18 |
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
|
Mar 14 |
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
|
Mar 13 |
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
|
Jan 29 |
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
|
Dec 27 |
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
|
Dec 18 |
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
|
Dec 14 |
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
|
Nov 21 |
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
|